
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
New York - Although relatively uncommon in African Americans, skin cancer does occur in this group and often in atypical or advanced forms.